BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17431113)

  • 1. Identification of a novel inhibitor of urokinase-type plasminogen activator.
    Zhu M; Gokhale VM; Szabo L; Munoz RM; Baek H; Bashyam S; Hurley LH; Von Hoff DD; Han H
    Mol Cancer Ther; 2007 Apr; 6(4):1348-56. PubMed ID: 17431113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor.
    Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA
    Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
    Gladysz R; Adriaenssens Y; De Winter H; Joossens J; Lambeir AM; Augustyns K; Van der Veken P
    J Med Chem; 2015 Dec; 58(23):9238-57. PubMed ID: 26575094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
    Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
    Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library.
    Li CY; de Veer SJ; Law RHP; Whisstock JC; Craik DJ; Swedberg JE
    Chembiochem; 2019 Jan; 20(1):46-50. PubMed ID: 30225958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
    McGowen R; Biliran H; Sager R; Sheng S
    Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion.
    Okada SS; Grobmyer SR; Barnathan ES
    Arterioscler Thromb Vasc Biol; 1996 Oct; 16(10):1269-76. PubMed ID: 8857924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
    Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
    J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
    Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
    Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The urokinase-type plasminogen activator system and its role in tumor progression].
    Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
    Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents.
    Schweinitz A; Steinmetzer T; Banke IJ; Arlt MJ; Stürzebecher A; Schuster O; Geissler A; Giersiefen H; Zeslawska E; Jacob U; Krüger A; Stürzebecher J
    J Biol Chem; 2004 Aug; 279(32):33613-22. PubMed ID: 15150279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of urokinase type plasminogen activator and cytostatic activity from crude plants extracts.
    Zha X; Diaz R; Franco JJ; Sanchez VF; Fasoli E; Barletta G; Carvajal A; Bansal V
    Molecules; 2013 Jul; 18(8):8945-58. PubMed ID: 23896619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
    Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
    Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of molecular modeling to urokinase inhibitors development.
    Sulimov VB; Katkova EV; Oferkin IV; Sulimov AV; Romanov AN; Roschin AI; Beloglazova IB; Plekhanova OS; Tkachuk VA; Sadovnichiy VA
    Biomed Res Int; 2014; 2014():625176. PubMed ID: 24967388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
    Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
    J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation.
    Kobayashi H; Suzuki M; Kanayama N; Terao T
    Clin Exp Metastasis; 2004; 21(2):159-66. PubMed ID: 15168733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
    Nicholl SM; Roztocil E; Davies MG
    J Vasc Surg; 2005 Apr; 41(4):672-81. PubMed ID: 15874933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of the protease domain of urokinase-type plasminogen activator.
    Rockway TW; Nienaber V; Giranda VL
    Curr Pharm Des; 2002; 8(28):2541-58. PubMed ID: 12369939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.